Opioid Use Disorder Treatment and Recovery in BIPOC Communities: Webinar Series

Aug 24, 2022

In 2020, among the 2.7 million people with an opioid use disorder in the U.S., only 11.2% received any of the three medications for opioid use disorder (MOUD), despite it being the gold standard of care for opioid use disorder (OUD). Racial disparities and inequities further hinder Black, Indigenous and People of Color (BIPOC) populations with OUD from accessing the treatment and care that they need. Data from a Centers for Disease Control and Prevention (CDC) report found that rates of drug overdose death in 2020 increased by 44% for Black individuals, 40% for Hispanic/Latino individuals and 39% for Native individuals, yet all access treatment at lower rates than White individuals, who saw a 22% increase in overdose death.

To assist providers in better addressing these racial disparities, the National Council for Mental Wellbeing, with support from the Providers Clinical Support System (PCSS), developed a three-part webinar series addressing OUD treatment and recovery in BIPOC communities. This webinar series provides historical context and highlights the work of four experts from the field as they present culturally centered approaches to increase engagement in and access to treatment and recovery for Black, Hispanic/Latino and Native populations.

The goal of PCSS is to train healthcare professionals in evidence-based practices for the prevention and treatment of OUD and substance use disorders more broadly. Learn more about PCSS.


  1. Substance Abuse and Mental Health Services Administration. (2021). Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/.
  2. Kariisa, M., Davis, N. L., Kumar, S., Seth, P., Mattson, C. L., Chowdhury, F., & Jones, C. M. (2022). Vital Signs: Drug Overdose Deaths, by Selected Sociodemographic and Social Determinants of Health Characteristics – 25 States and the District of Columbia, 2019-2020. Morbidity and Mortality Weekly Report (MMWR), 71(29), 940-947. http://dx.doi.org/10.15585/mmwr.mm7129e2.
  3. Friedman, J. R. & Hansen, H. (2022). Evaluation of Increases in Drug Overdose Mortality Rates in the US by Race and Ethnicity Before and During the COVID-19 Pandemic. JAMA Psychiatry, 79(4), 379-381. https://doi.org/10.1001/jamapsychiatry.2022.0004.

Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.